G1 Therapeutics, Inc.
GTHXNext catalyst
Lurbinectedin
Lung Cancer
Get an email about GTHX's next catalysts
Track G1 Therapeutics (GTHX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
Lurbinectedin Phase 2 Est. Readout
Estimated primary completion for Lurbinectedin trial (NCT05578326) in Lung Cancer. Topline data typically follows completion by weeks to months.
SourceTrilaciclib Phase 2 Est. Readout
Estimated primary completion for Trilaciclib trial (NCT05578326) in Lung Cancer. Topline data typically follows completion by weeks to months.
SourceTrilaciclib Phase 2 Est. Readout (ToPCourT)
Estimated primary completion for Trilaciclib trial (NCT06027268) in Metastatic Triple-Negative Breast Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Trilaciclib
TNBC - Triple-Negative Breast Cancer
Trilaciclib, carboplatin, etoposide，or Topotecan
Extensive-stage Small-cell Lung Cancer
G1T38
Carcinoma, Non-Small-Cell Lung
Cylophosphamide
Triple Negative Breast Cancer
Lurbinectedin
Lung Cancer
Carboplatin (Investigator discretion)
Triple Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trilaciclib | Phase 3 | TNBC - Triple-Negative Breast Cancer | - | - |
Trilaciclib, carboplatin, etoposide，or Topotecan | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
G1T38 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Cylophosphamide | Phase 2 | Triple Negative Breast Cancer | - | - |
Lurbinectedin | Phase 2 | Lung Cancer | - | - |
Carboplatin (Investigator discretion) | Phase 2 | Triple Negative Breast Cancer | - | - |
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Triple Negative Breast Cancer
1 drug in this indication
TNBC - Triple-Negative Breast Cancer
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in G1 Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in G1 Therapeutics, Inc.'s (GTHX) pipeline across Phase 3, Phase 2. Its lead program is Trilaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is G1 Therapeutics, Inc.'s next FDA catalyst?→
G1 Therapeutics, Inc.'s (GTHX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GTHX biotech catalysts?→
Add GTHX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow G1 Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.